Boston Scientific is a global medical technology company that specializes in the development, manufacturing, and marketing of a wide range of medical devices and solutions. The company focuses on providing innovative therapies for various medical conditions, including those affecting the cardiovascular, urology, and gastrointestinal systems, among others. Boston Scientific is committed to advancing patient care through its pioneering technologies, which are designed to improve outcomes and enhance the quality of life for patients around the world. Their product offerings include devices for minimally invasive procedures, enabling healthcare professionals to deliver high-quality care efficiently and effectively. Read More
The first quarter of 2026 has signaled a definitive end to the "deal drought" that plagued the previous three years, as American corporations embark on an unprecedented wave of consolidation. Driven by a hunger for artificial intelligence (AI) infrastructure, a stabilizing interest rate environment, and landmark tax legislation, the U.
As of April 1, 2026, the global medical technology landscape is undergoing a profound shift, and at the center of this evolution is Medtronic plc (NYSE: MDT). Long regarded as the "sleeping giant" of the healthcare sector, Medtronic has spent the last three years in the throes of a massive structural and cultural overhaul. Today, [...]
As we enter the second quarter of 2026, Johnson & Johnson (NYSE: JNJ) stands as a starkly different entity than the consumer-facing conglomerate that defined the 20th century. Having successfully shed its legacy consumer health business and weathered the initial storm of its largest patent cliff in a decade, J&J has rebranded itself as a [...]
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Date: March 31, 2026 Introduction Boston Scientific Corporation (NYSE: BSX) finds itself at a critical crossroads this morning. After a year of record-breaking growth and the successful launch of its Pulsed Field Ablation (PFA) portfolio, the stock is experiencing a sharp intraday decline of 4.2% today, March 31, 2026. This move comes despite the recent [...]
Check out the companies making headlines yesterday: Avis Budget Group (NASDAQ:CAR): Car rental services provider Avis (NASDAQ:CAR) fell by 9% on Monday after...
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) between July 23, 2025 and February 3, 2026, inclusive.
What Happened? Shares of medical device company Boston Scientific (NYSE:BSX) fell 9.4% in the afternoon session after Raymond James downgraded the stock to O...
The global mergers and acquisitions (M&A) market has roared back to life in the first quarter of 2026, shattering expectations and signaling a definitive end to the dealmaking drought of previous years. As of late March, total announced deal volume has surged past the $1 trillion milestone, a 27%
NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Boston Scientific To Contact Him Directly To Discuss Their Options
NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Levi & Korsinsky, LLP alerts investors in Boston Scientific Corporation (NYSE: BSX) of a pending securities class action. Class Period: July 23, 2025 through February 3, 2026. Check if you can recover your investment losses or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com | (212) 363-7500.
NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) between July 23, 2025 and February 3, 2026, inclusive.
As the first quarter of 2026 draws to a close, the U.S. financial landscape has been reshaped by a staggering surge in corporate consolidation. Total deal value for the quarter reached a historic $813.3 billion, a massive 50% increase over the same period last year. This record-breaking figure
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Boston Scientific To Contact Him Directly To Discuss Their Options
